

MEDICINES CO /DE
Form 8-K
June 01, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 25, 2006**

The Medicines Company

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction
of Incorporation)

000-31191

(Commission
File Number)

04-3324394

(IRS Employer
Identification No.)

8 Campus Drive

Parsippany, New Jersey

(Address of Principal Executive Offices)

07054

(Zip Code)

Registrant's telephone number, including area code: **(973) 656-1616**

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: MEDICINES CO /DE - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01. Entry into a Material Definitive Agreement.

On May 25, 2006, at the 2006 annual meeting of stockholders of The Medicines Company (the Registrant), the Registrant s stockholders approved an amendment to the Registrant s 2004 Stock Incentive Plan increasing the number of shares of the Registrant s common stock issuable under that plan from 4,400,000 to 8,800,000 and an amendment to the Registrant s 2000 Employee Stock Purchase Plan increasing the number of shares of the Registrant s common stock issuable under that plan from 255,500 to 505,500. These amendments became effective upon stockholder approval.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE MEDICINES COMPANY

Date: June 1, 2006

By:

/s/ PAUL M. ANTINORI
Paul M. Antinori
Vice President and General Counsel

3
